相关实验视频
Updated: Jul 9, 2025

Preparation of Exosomes for siRNA Delivery to Cancer Cells
Published on: December 5, 2018
最近基于外体的免疫疗法的进展适用于癌症
Jindong Xie1,2, Zihan Zheng3, Ling Tuo3
1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
外体,细胞中的微小囊泡,通过调节免疫反应,显示出癌症免疫治疗的前景. 用治疗剂包装外体细胞增强了它们对癌症治疗策略的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 纳米医学是一种纳米医学.
背景情况:
- 癌症是全球死亡的主要原因,推动了对新型治疗策略的需求.
- 细胞外囊泡,特别是外体,正在成为癌症免疫治疗的有希望的候选人.
- 外基因组具有固有的特性,如免疫性和分子转移能力,使其在癌症治疗中具有价值.
研究的目的:
- 总结和评估在癌症免疫治疗中利用外体细胞的策略.
- 探索包装外体体与外源性货物的潜力,以增强治疗效果.
- 审查外体在癌症治疗中的多种免疫调节作用.
主要方法:
- 对基于外体的癌症治疗研究的文献综述.
- 对外体的免疫调节作用 (抑制/促进免疫反应,途径调节) 的分析.
- 评估外体细胞作为抗瘤药物和外源性货物的载体.
主要成果:
- 来自不同细胞起源的外体体表现出各种治疗效果.
- 外体可以被设计为提供治疗有效载荷,增强抗瘤活性.
- 外体的免疫调节功能是多方面的,影响免疫反应和信号通路.
结论:
- 基于外体的策略具有促进癌症免疫治疗的巨大潜力.
- 具有特定载荷的工程外体是提高癌症治疗疗效的关键发展.
- 对外体工程和输送的进一步研究对于临床翻译至关重要.
更多相关视频
08:49Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
08:02In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...